
Yonsei Cancer Center present positive P1 results for next-gen KRAS G12C inhibitor treatment
A research team at Yonsei Cancer Center found that D3S-001, a new KRAS G12C-targeting therapy being developed by D3 Bio, a Chinese biotech, has demonstrated a promising objective response rate of 73.5 percent in a phase 1 trial involving patients with …